A Phase 1/2, Open-Label, First-in-human, Multiple Ascending Dose Multicenter Study of MT-101 in Subjects With CD5+ Relapsed/Refractory T Cell Lymphoma
Latest Information Update: 20 Nov 2023
At a glance
- Drugs MT-101 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions; First in man
- Acronyms IMAGINE
- Sponsors Myeloid Therapeutics
- 09 Nov 2023 Planned End Date changed from 1 Oct 2024 to 1 Oct 2025.
- 09 Nov 2023 Planned primary completion date changed from 1 Nov 2023 to 1 Nov 2024.
- 09 Nov 2023 Status changed from recruiting to suspended.